Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
November 27, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx...
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
November 13, 2023 08:10 ET
|
Royalty Pharma plc
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophreniaPhase 3 data...
Royalty Pharma Reports Third Quarter 2023 Results
November 08, 2023 07:00 ET
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $574 million and Adjusted Cash Receipts(1) (non-GAAP) of $637 millionAnnounced transactions of up to $3.8 billion year-to-date, including $2.1...
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
October 19, 2023 07:59 ET
|
Royalty Pharma plc
Royalty Pharma purchases a portion of royalties on Roche’s Evrysdi for $1.0 billion upfrontPTC Therapeutics has option to sell rest of royalty for up to $500 million; Royalty Pharma has option to buy...
Royalty Pharma Declares Fourth Quarter 2023 Dividend
October 16, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2023 of $0.20 per Class A...
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
October 11, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the...
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
September 21, 2023 08:25 ET
|
Royalty Pharma plc
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also...
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 05, 2023 16:15 ET
|
Royalty Pharma plc
• Proceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE)...
Royalty Pharma to Present at Upcoming Investor Conferences
September 05, 2023 08:25 ET
|
Royalty Pharma plc
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: ...
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
August 24, 2023 06:30 ET
|
Royalty Pharma plc
Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin®...